Compare TGL & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGL | HCWB |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 5.0M |
| IPO Year | 2022 | 2021 |
| Metric | TGL | HCWB |
|---|---|---|
| Price | $2.52 | $2.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 119.9K | 117.7K |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,330,557.00 | ★ $4,099,750.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.26 | $0.25 |
| 52 Week High | $58.00 | $6.11 |
| Indicator | TGL | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 41.45 | 47.53 |
| Support Level | $2.04 | $2.35 |
| Resistance Level | $3.31 | $4.12 |
| Average True Range (ATR) | 0.27 | 0.44 |
| MACD | 0.03 | 0.07 |
| Stochastic Oscillator | 35.09 | 44.63 |
Treasure Global Inc has created an online-to-offline e-commerce platform business model that offers consumers and merchants instant rebates and affiliate cashback programs, while providing a seamless e-payment solution with rebates in both e-commerce and physical retail or merchant settings. Its product is an internet application branded as the ZCITY app, which targets consumers by providing personalized deals based on their purchase history, location, and preferences. The Company has two reportable segments: payment processing and e-commerce operation in its ZCITY platform, and customized software development service, and the majority of revenue comes from payment processing and e-commerce operation in its ZCITY platform.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.